Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes

Transplantation

Volumn 94, Issue 5, 2012, Pages 506-512

  Trofe Clark, Jennifer ^a,b   Reese, Peter P ^b,c   Patel, Hina J ^b   Jakobowski, Diane ^a   Goral, Simin ^b   Doll, Stacey L ^a   Abt, Peter L ^b   Bloom, Roy D ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immunosuppression; Induction; Kidney transplant; Outcomes; Rabbit antithymocyte globulin

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HOSPITAL COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANIMALS; ANTILYMPHOCYTE SERUM; BIOPSY; COST SAVINGS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITAL COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INPATIENTS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT READMISSION; PHILADELPHIA; RABBITS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866341753     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31825c58c0     Document Type: Article

References (19)

1. \, antithymocyte globulin (rabbit); United States Prescribing Information [online]. Available at http://www.thymoglobulin.com/home/thymo-pdf-pi.pdf. Accessed November 4, 2011.
2. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86: 947.
3. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511.
4. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; CD003897.
5. Brennan DC, Schnitzler MA. Long-term results of rabbit anti-thymocyte globulin and basiliximab induction. N Engl J Med 2008; 359: 1736.
6. Mueller TF. Mechanisms of action of Thymoglobulin. Transplantation 2007; 84: S5.
7. Deeks ED, Keating GM. Rabbit antithymocyte globulin (Thymoglob-ulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009; 69: 1483.
8. Gaber AO, Monaco AP, Russell JA, et al. Rabbit antithymocyte globulin (Thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010; 70: 691.
9. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
10. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299.
11. + lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73: 1514.
12. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosup-pression for organ transplantation. Lancet 2003; 361: 1502.
13. Stevens RB, Lane JT, Boerner BP, et al. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant 2012; 26: 123.
14. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011. Available at http://www.srtr.org/annual-reports/2010/506a-ki.htm. Accessed November 4, 2011.
15. Marvin MR, Droogan C, Sawinski D, et al. Administration of rabbit antithymocyte globulin (Thymoglobulin) in ambulatory renal-transplant patients. Transplantation 2003; 75: 488.
16. Wiland AM, Fink JC, Philosophe B, et al. Peripheral administration of Thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc 2001; 33: 1910. (Pubitemid 32238116)
17. Mathis AS, Rao V. Deep vein thrombosis during rabbit antithymocyte globulin administration. Transplant Proc 2004; 36: 3250.
18. Erickson AL, Roberts K, Malek SK, et al. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. Transpl Int 2010; 23: 636.
19. Trissel LA, Saenz CA. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health Syst Pharm 2003; 60: 1650.